217526-52-8

Basic information

• Product Name: 4,5-DIHYDRO-1H-FURO[2,3-G]INDAZOLE
• Synonyms: 4,5-DIHYDRO-1H-FURO[2,3-G]INDAZOLE
• CAS NO: 217526-52-8
• Molecular Formula: C9H8N2O
• Molecular Weight: 160.175
• Mol File: 217526-52-8.mol

Chemical Properties

• Boiling Point: 375.6±22.0 °C(Predicted)
• Appearance: /
• Density: 1.330±0.06 g/cm3(Predicted)
• PKA: 13.66±0.20(Predicted)
• CAS DataBase Reference: 4,5-DIHYDRO-1H-FURO[2,3-G]INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 4,5-DIHYDRO-1H-FURO[2,3-G]INDAZOLE(217526-52-8)
• EPA Substance Registry System: 4,5-DIHYDRO-1H-FURO[2,3-G]INDAZOLE(217526-52-8)

Safety Data

• Hazardous Substances Data: 217526-52-8(Hazardous Substances Data)

Upstream product

• 162794-47-0 5-hydroxymethylene-4,5,6,7-tetrahydrobenzofuran-4-one enol form 

Downstream Products

• 372163-81-0 1-(4,5-dihydro-1H-furo[2,3-g]indazol-7-yl)ethanone 
• 57174-47-7 1H-furo[2,3-g]indazole 

Relevant articles and documents

FUROINDAZOLE DERIVATIVES

The present invention covers furoindazole compounds of general formula (I): in which (I) are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of autoimmune diseases such as multiple sclerosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, primary and secondary autoimmune uveitis, inflammatory disorders like endometriosis, inflammatory eye diseases, inflammatory kidney diseases, inflammatory liver diseases like non-alcoholic, alcoholic- and toxic fatty liver diseases, lung diseases like asthma, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and metabolic and metabolic-endocrine disorders like metabolic syndrome, insulin resistance, diabetes mellitus type I and type II, and polycystic ovary syndrome (PCOS) disorders, neuropathic and inflammatory pain disorders in humans and animals.

Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo[2,3-g]indazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists

A series of novel indazole derivatives were synthesized, and their structure-activity relationships examined in order to identify potent and selective 5-HT2C receptor agonists. Among these compounds, (S)-2-(7-ethyl-1H-furo[2,3-g]indazol-1-yl)-1-methylethylamine (YM348) had a good in vitro profile, that is, high agonistic activity to the human 5-HT2C receptor subtype (EC50 = 1.0 nM) and high selectivity over 5-HT2A receptors. This compound was also effective in a rat penile erection model when administered po.

An efficient preparative route to 7-ethyl-1H-furo[2,3-g]indazole

A new and efficient route to 7-ethyl-1H-furo[2,3-g]indazole (2) has been developed. Treatment of 4,5-dihydro-7-(1-hydroxyethyl)indazole (12) with hydrochloric acid in ethanol resulted in a concomitant dehydration and aromatization to afford the title compound in good yield.